Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

This study investigates whether people with early relapsing multiple sclerosis (MS) can safely stop or reduce their treatment with ocrelizumab — an infusion given every 6 months — after achieving stable disease. MS medications carry long-term risks, so understanding whether treatment can be safely paused is important for patients. **You may be eligible if...** - You have been diagnosed with multiple sclerosis meeting the McDonald 2017 criteria - Your disease has not progressed for a period of time (specific disease duration criteria apply) - You are a woman of childbearing potential and willing to use effective contraception during the study and for 6 months after the last dose **You may NOT be eligible if...** - Your disease has been present for more than 3 years since first symptom (at time of consent) - You have an active infection or significant other medical condition - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.